4 ms·

The article is one sided. Is there data that proves that 1 dose of J&J has advantages over 1 dose of Moderna / Pfizer vaccine? Right now these people are giving

The article is one sided. Is there data that proves that 1 dose of J&J has advantages over 1 dose of Moderna / Pfizer vaccine? Right now these people are giving space for other people to get vaccinated, so what they are doing can save lives (Just like what happened in UK)

vmception 6y ago
I wonder this too, the non-mRNA vaccines are inferior technology
- nocommentguy 6y ago
  Inferior in the same way your chrome sandbox is inferior to node because it can’t access system files.
- dwarfsandstuff 6y ago
  I'll take inferior and well tested over superior and untested any time.
  - vmception 6y ago
    which has nothing to do with determining efficacy of a single shot mRNA vaccine and a single shot non-mRNA vaccine
T-A 6y ago
From the J&J trial results [1]: Vaccine efficacy (VE) against central laboratory-confirmed moderate to severe/critical COVID19 across all geographic areas in which the trial was conducted was 66.9% (95% CI 59.0, 73.4) when considering cases occurring at least 14 days after the single-dose vaccination and 66.1% (55.0, 74.8) when considering cases occurring at least 28 days after vaccination. I have seen estimates as low as 40-something % for single doses of the mRNA vaccines, but this may have been an underestimate caused by only considering the first two weeks after inoculation. Given enough time for immunity to fully set in, the real number may be over 90% [2]. HOWEVER, those numbers all refer to symptomatic disease. Prevention of hospitalization and death was 100% in the J&J trial. [1] https://www.fda.gov/media/146217/download https://www.fda.gov/media/146217/download [2] https://www.nejm.org/doi/full/10.1056/NEJMc2036242 https://www.nejm.org/doi/full/10.1056/NEJMc2036242
- xiphias2 6y ago
  There’s a big difference between 2 weeks and 1 month, we know that now. Also the main concerns of the article are long term protection and protection against new variants. Both of these issues can wait until more people are vaccinated, and again we don’t have long term data on J&J vaccine, and I don’t see why it would be better than the mRNA vaccines.

vmception 6y ago

I wonder this too, the non-mRNA vaccines are inferior technology

nocommentguy 6y ago
Inferior in the same way your chrome sandbox is inferior to node because it can’t access system files.
dwarfsandstuff 6y ago
I'll take inferior and well tested over superior and untested any time.
- vmception 6y ago
  which has nothing to do with determining efficacy of a single shot mRNA vaccine and a single shot non-mRNA vaccine

T-A 6y ago

From the J&J trial results [1]: Vaccine efficacy (VE) against central laboratory-confirmed moderate to severe/critical COVID19 across all geographic areas in which the trial was conducted was 66.9% (95% CI 59.0, 73.4) when considering cases occurring at least 14 days after the single-dose vaccination and 66.1% (55.0, 74.8) when considering cases occurring at least 28 days after vaccination. I have seen estimates as low as 40-something % for single doses of the mRNA vaccines, but this may have been an underestimate caused by only considering the first two weeks after inoculation. Given enough time for immunity to fully set in, the real number may be over 90% [2]. HOWEVER, those numbers all refer to symptomatic disease. Prevention of hospitalization and death was 100% in the J&J trial. [1] https://www.fda.gov/media/146217/download https://www.fda.gov/media/146217/download [2] https://www.nejm.org/doi/full/10.1056/NEJMc2036242 https://www.nejm.org/doi/full/10.1056/NEJMc2036242

xiphias2 6y ago
There’s a big difference between 2 weeks and 1 month, we know that now. Also the main concerns of the article are long term protection and protection against new variants. Both of these issues can wait until more people are vaccinated, and again we don’t have long term data on J&J vaccine, and I don’t see why it would be better than the mRNA vaccines.